Kymera Investor Presentation Deck
Validated Platform and Discovery Engine
Demonstrated predictable translation of PK, PD and Safety in 3 oncology and immunology programs
●
Successfully Applied TPD to Unmet Needs Outside of Oncology
Reported clinical impact in complex inflammatory diseases such as HS and AD
●
What Our Recent Accomplishments Mean for Kymera and TPD
Demonstrated TPD Can Lead to Differentiated Clinical Activity Compared to Small
Molecule Inhibitors
Initial KT-474 data in HS and AD validates Kymera's unique target selection strategy
●
Kymera is Building Franchises in Both Immunology and Oncology
Focus is on areas of high unmet needs and large commercial opportunity, in targets with clear
degrader rationale
●
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
PAGE 5View entire presentation